Sarmad Sadeghi, MD, PhD

Dr. Sarmad Sadeghi earned his medical degree at Tehran University of Medical Sciences. He has a Master of Science degree (MS) in Health Information Sciences and a Doctor of Philosophy degree (PhD) in Public Health Management and Policy Sciences from the University of Texas Health Sciences Center at Houston.
He completed his internal medicine residency at the University of Texas Medical School at Houston and the Cleveland Clinic Foundation. He completed his hematology/oncology fellowship at the Cleveland Clinic Taussig Cancer Institute. Dr. Sadeghi joined the faculty at the division of oncology of University of Southern California in 2013 and has a clinical and research focus in genitourinary malignancies, specifically bladder, kidney and prostate cancers.
Dr. Sadeghi is the study chair and principal investigator of a number of multicenter clinical trials and is also an active member of SWOG cooperative group and the California Cancer Consortium.
Dr. Sadeghi is well published with several original articles and abstracts in peer reviewed journals and international meetings.

• Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providersUrol Oncol. 2017 07; 35(7):459. e15-459. e24. . View in PubMed
• EphrinB2: Expression of a novel potential target in renal cell carcinoma Indian J Urol. 2023 Jul-Sep; 39(3):223-227. . View in PubMed
• EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma J Clin Oncol. 2023 01 20; 41(3):640-650. . View in PubMed
• The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy Cancers (Basel). 2022 Dec 03; 14(23). . View in PubMed
• EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy Pathol Res Pract. 2020 Jun; 216(6):152967. . View in PubMed
• Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database BMJ Open Gastroenterol. 2020 11; 7(1). . View in PubMed
• Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent StudiesClin Genitourin Cancer. 2020 10; 18(5):351-360. e3. . View in PubMed
• Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis Am J Clin Oncol. 2020 06; 43(6):428-434. . View in PubMed
• How to optimize cancer therapy when coronavirus hits the fanAm J Manag Care. 2020 06; 26(5 Spec No. ):SP167. . View in PubMed
• Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have? Eur Urol Focus. 2020 07 15; 6(4):623-626.. View in PubMed
• Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)Clin Genitourin Cancer. 2019 08; 17(4):241-247. e1. . View in PubMed
• Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer Urol Oncol. 2019 01; 37(1):1-11. . View in PubMed
• Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy Cancer. 2019 11 01; 125(21):3853-3863. . View in PubMed
• Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653) J Clin Oncol. 2019 10 10; 37(29):2682-2688. . View in PubMed
• Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. . View in PubMed
• Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. . View in PubMed
• Comparative effectiveness of screening strategies for colorectal cancer Cancer. 2017 05 01; 123(9):1516-1527. . View in PubMed
• Comparative effectiveness of screening strategies for Lynch syndrome J Natl Cancer Inst. 2015 Apr; 107(4). . View in PubMed
• Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. . View in PubMed
• Tivozanib in the treatment of renal cell carcinoma Biologics. 2013; 7:139-48. . View in PubMed
• Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder Semin Oncol. 2012 Oct; 39(5):608-14. . View in PubMed
• Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome Cancer. 2012 Jul 01; 118(13):3277-82. . View in PubMed
• Screening for Lynch syndrome in the general population-letter Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. . View in PubMed
• A Bayesian model for triage decision support Int J Med Inform. 2006 May; 75(5):403-11. . View in PubMed
• Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS Stud Health Technol Inform. 2005; 116:223-8. . View in PubMed
• Mitral valve recurrence of a left atrial myxoma Eur J Cardiothorac Surg. 2002 Mar; 21(3):568-73. . View in PubMed
• Determinants of operative mortality following primary coronary artery bypass surgery Eur J Cardiothorac Surg. 2002 Feb; 21(2):187-92. . View in PubMed
• Self-administered decision support tool for triage: results of a retrospective study Stud Health Technol Inform. 2002; 85:45-51. . View in PubMed

• Daneshmand, Siamak
• Lenz, Heinz-Josef
• Djaladat, Hooman
• Gill, Inderbir
• Quinn, David
• Desai, Mihir
• Cacciamani, Giovanni